1. Rare germline genetic variants and risk of aggressive prostate cancer.
- Author
-
Nguyen-Dumont T, MacInnis RJ, Steen JA, Theys D, Tsimiklis H, Hammet F, Mahmoodi M, Pope BJ, Park DJ, Mahmood K, Severi G, Bolton D, Milne RL, Giles GG, and Southey MC
- Subjects
- Aged, BRCA2 Protein genetics, Cohort Studies, Genetic Predisposition to Disease genetics, Genetic Testing methods, Genotype, Humans, Male, Middle Aged, Prostate pathology, Prostate-Specific Antigen genetics, Prostatic Neoplasms pathology, Germ Cells metabolism, Germ-Line Mutation genetics, Prostatic Neoplasms genetics
- Abstract
Few genetic risk factors have been demonstrated to be specifically associated with aggressive prostate cancer (PrCa). Here, we report a case-case study of PrCa comparing the prevalence of germline pathogenic/likely pathogenic (P/LP) genetic variants in 787 men with aggressive disease and 769 with nonaggressive disease. Overall, we observed P/LP variants in 11.4% of men with aggressive PrCa and 9.8% of men with nonaggressive PrCa (two-tailed Fisher's exact tests, P = .28). The proportion of BRCA2 and ATM P/LP variant carriers in men with aggressive PrCa exceeded that observed in men with nonaggressive PrCa; 18/787 carriers (2.3%) and 4/769 carriers (0.5%), P = .004, and 14/787 carriers (0.02%) and 5/769 carriers (0.01%), P = .06, respectively. Our findings contribute to the extensive international effort to interpret the genetic variation identified in genes included on gene-panel tests, for which there is currently an insufficient evidence-base for clinical translation in the context of PrCa risk., (© 2020 UICC.)
- Published
- 2020
- Full Text
- View/download PDF